Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 4/20 | 0.69 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.69 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | MMP13 | P45452 | 1/20 | 0.50 |
| ▸ | APEX1 | P27695 | 1/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3103577 | 0.89 | HSP90AA1 (0.67) | HSP90AA1HSP90AB1MAPTALDH1A1KDM4E | |
| SCHEMBL13151404 | 0.87 | HSP90AA1 (0.64) | HSP90AA1HSP90AB1 | |
| SCHEMBL5748915 | 0.85 | HSP90AA1 (0.57) | HSP90AA1HSP90AB1MAPTALDH1A1MMP13 | |
| SCHEMBL3096292 | 0.83 | HSP90AA1 (0.68) | HSP90AA1HSP90AB1HPGDKMT2AMEN1 | |
| SCHEMBL13151378 | 0.83 | HSP90AA1 (0.67) | HSP90AA1HSP90AB1RAB9AMAPTALDH1A1 | |
| SCHEMBL3103510 | 0.83 | HSP90AA1 (0.53) | HSP90AA1HSP90AB1MAPTHPGDALDH1A1 | |
| SCHEMBL3082929 | 0.82 | HSP90AA1 (0.53) | HSP90AA1HSP90AB1HPGDKMT2AMEN1 | |
| SCHEMBL3096102 | 0.81 | HSP90AA1 (0.64) | HSP90AA1HSP90AB1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL3097536 | 0.80 | HSP90AA1 (0.53) | HSP90AA1HSP90AB1 | |
| SCHEMBL3096215 | 0.79 | HSP90AA1 (0.56) | HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803831-B2 | 3-(2-hydroxy-phenyl)-1H-pyrazole-4-carboxylic acid amide derivatives as HSP90 inhibitors for the treatment of cancer | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2010-09-28 | — | — | US | claimed |
| US-20070112192-A1 | 3-(2-Hydroxy-phenyl)-1h-pyrazole-4-carboxylic acid amide derivatives as hsp90 inhibitors for the treatment of cancer | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2007-05-17 | — | — | US | claimed |
| EP-1567151-B1 | 3-(2-HYDROXY-PHENYL)-1H-PYRAZOLE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS HSP90 INHIBITORS FOR THE TREATMENT OF CANCER | VERNALIS CAMBRIDGE LTD (GB) | 2006-03-15 | — | — | EP | claimed |
| EP-1567151-A1 | 3-(2-HYDROXY-PHENYL)-1H-PYRAZOLE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS HSP90 INHIBITORS FOR THE TREATMENT OF CANCER | Vernalis (Cambridge) Limited (GB) | 2005-08-31 | — | — | EP | claimed |
| WO-2004050087-A1 | 3-(2-HYDROXY-PHENYL)-1H-PYRAZOLE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS HSP90 INHIBITORS FOR THE TREATMENT OF CANCER | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2004-06-17 | — | — | WO | claimed |
| US-7803831-B2 | 3-(2-hydroxy-phenyl)-1H-pyrazole-4-carboxylic acid amide derivatives as HSP90 inhibitors for the treatment of cancer | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2010-09-28 | — | — | US | disclosed |
| US-7803831-B2 | 3-(2-hydroxy-phenyl)-1H-pyrazole-4-carboxylic acid amide derivatives as HSP90 inhibitors for the treatment of cancer | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2010-09-28 | — | — | US | disclosed |
| US-7803956-B2 | Benzofuran derivatives useful for treating hyper-proliferative disorders | BAYER PHARMACEUTICALS CORPORATION (US) | 2010-09-28 | — | — | US | disclosed |
| US-7803831-B2 | 3-(2-hydroxy-phenyl)-1H-pyrazole-4-carboxylic acid amide derivatives as HSP90 inhibitors for the treatment of cancer | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2010-09-28 | — | — | US | disclosed |
| US-7659412-B2 | Benzofuran derivatives useful for treating hyper-proliferative disorders | BAYER HEALTHCARE LLC (US) | 2010-02-09 | — | — | US | disclosed |
| US-20090292014-A1 | BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | ZHANG CHENGZHI | 2009-11-26 | — | — | US | disclosed |
| US-20090023783-A1 | BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | ZHANG CHENGZHI | 2009-01-22 | — | — | US | disclosed |
| US-20070112192-A1 | 3-(2-Hydroxy-phenyl)-1h-pyrazole-4-carboxylic acid amide derivatives as hsp90 inhibitors for the treatment of cancer | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2007-05-17 | — | — | US | disclosed |
| US-20070112192-A1 | 3-(2-Hydroxy-phenyl)-1h-pyrazole-4-carboxylic acid amide derivatives as hsp90 inhibitors for the treatment of cancer | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2007-05-17 | — | — | US | disclosed |
| US-20060194816-A1 | Benzofuran derivatives useful for treating hyper-proliferative disorders | BAER PHAMACEUTICALS CORPORATION (US) | 2006-08-31 | — | — | US | disclosed |
| EP-1654245-A1 | BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | Bayer Pharmaceuticals Corporation (US) | 2006-05-10 | — | — | EP | disclosed |
| EP-1567151-B1 | 3-(2-HYDROXY-PHENYL)-1H-PYRAZOLE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS HSP90 INHIBITORS FOR THE TREATMENT OF CANCER | VERNALIS CAMBRIDGE LTD (GB) | 2006-03-15 | — | — | EP | disclosed |
| EP-1567151-A1 | 3-(2-HYDROXY-PHENYL)-1H-PYRAZOLE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS HSP90 INHIBITORS FOR THE TREATMENT OF CANCER | Vernalis (Cambridge) Limited (GB) | 2005-08-31 | — | — | EP | disclosed |
| WO-2005014566-A1 | BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-02-17 | — | — | WO | disclosed |
| WO-2004050087-A1 | 3-(2-HYDROXY-PHENYL)-1H-PYRAZOLE-4-CARBOXYLIC ACID AMIDE DERIVATIVES AS HSP90 INHIBITORS FOR THE TREATMENT OF CANCER | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090292014-A1 | BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | PCNA, MKI67, CDK4 | HSP90AA1 672/4885HSP90AB1 442/4885RAB9A 4187/4885 |
| US-20070112192-A1 | 3-(2-Hydroxy-phenyl)-1h-pyrazole-4-carboxylic acid amide derivatives as hsp90 inhibitors for the treatment of cancer | HSP90AB1, HSP90AA1, HSP90AB2P | HSP90AA1 2/4885HSP90AB1 1/4885RAB9A 2454/4885 |
| US-20060194816-A1 | Benzofuran derivatives useful for treating hyper-proliferative disorders | MKI67, PCNA, CCNI | HSP90AA1 655/4885HSP90AB1 409/4885RAB9A 4278/4885 |
| US-20090023783-A1 | BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS | PCNA, MKI67, CDK4 | HSP90AA1 672/4885HSP90AB1 442/4885RAB9A 4187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.